Dipartimento di Scienze Farmaceutiche, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy.
Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.
CB2 receptor ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Using our previously described series of 1,8-naphthyridin-2(1H)-on-3-carboxamides as a lead class, several nitrogen heterocyclic derivatives, characterized by different central cores, were synthesized and tested for their affinity toward the human CB1 and CB2 cannabinoid receptors. The obtained results suggest that the new series of quinolin-2(1H)-on-3-carboxamides, 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides and 1,2-dihydro-2-oxopyridine-3-carboxamides represent novel scaffolds very suitable for the development of promising CB2 ligands. Furthermore, the newly synthesized CB2 ligands inhibit proliferation of several cancer cell lines. In particular, it was demonstrated that in DU-145 cell line these ligands exert a CB2-mediated anti-proliferative action and decrease the CB2 receptor expression levels.
由于该受体在几种生理病理过程中的潜在作用,CB2 受体配体正成为越来越有吸引力的药物。使用我们之前描述的一系列 1,8-萘啶-2(1H)-酮-3-甲酰胺作为先导化合物,合成了具有不同中心核的几种氮杂环衍生物,并对其与人类 CB1 和 CB2 大麻素受体的亲和力进行了测试。获得的结果表明,新系列的喹啉-2(1H)-酮-3-甲酰胺、4-羟基-2-氧代-1,2-二氢-1,8-萘啶-3-甲酰胺和 1,2-二氢-2-氧代吡啶-3-甲酰胺代表了非常适合开发有前途的 CB2 配体的新型支架。此外,新合成的 CB2 配体抑制了几种癌细胞系的增殖。特别是,已经证明这些配体在 DU-145 细胞系中发挥 CB2 介导的抗增殖作用,并降低 CB2 受体表达水平。